Abstracts Archive - Page 2459 of 2607 - ACR Meeting Abstracts

Abstract Number: 2165 • 2012 ACR/ARHP Annual Meeting
Utility of Vectra-DA™ On Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response: Results of a Pilot Study From a Phase 3 Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Sarah Lamberth, Yauheniya Cherkas, Carrie Brodmerkel and Mark Curran, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: Currently, disease activity in Rheumatoid Arthritis (RA) is measured using scoring systems that rely primarily on a collection of subjective measures from patients and…
Abstract Number: 2166 • 2012 ACR/ARHP Annual Meeting
Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Inger Byrjalsen³, Andrew Kenwright⁴, Adam Platt⁴, Thierry Sornasse⁵ and Claus Christiansen⁶, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Roche, Welwyn Garden City, United Kingdom, ⁵Product Development Immunology, Genentech, Inc., South San Francisco, USA, San Fransisco, CA, ⁶CCBR, Ballerup, Denmark
Background/Purpose: RA is characterized by poly-articular synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease…
Abstract Number: 2167 • 2012 ACR/ARHP Annual Meeting
Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab
Anne C. Bay-Jensen¹, Inger Byrjalsen², Claus Christiansen³ and Morten Asser Karsdal⁴, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³CCBR, Ballerup, Denmark, ⁴Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: RA is characterized by synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease early…
Abstract Number: 2168 • 2012 ACR/ARHP Annual Meeting
Tolerance and Efficacy of Rituximab in Elderly Patients with Rheumatoid Arthritis Enrolled in the French Society of Rheumatology Air Registry
Sarah Payet¹, Jacques-Eric Gottenberg², Xavier Mariette³, Philippe Ravaud⁴, Elodie Perrodeau⁵, Thomas Bardin⁶, Patrice Cacoub⁷, Alain G. Cantagrel⁸, Bernard Combe⁹, Maxime Dougados¹⁰, Rene-Marc Flipo¹¹, Bertrand Godeau¹², Loic Guillevin¹³, Xavier X. Le Loet¹⁴, Eric Hachulla¹⁵, Thierry Schaeverbeke¹⁶, Jean Sibilia¹⁷, Isabelle Pane¹⁸, Gabriel Baron¹⁹ and Martin Soubrier²⁰, ¹Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ²Rheumatology, Strasbourg University Hospital, Strasbourg, France, ³Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁴Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁵Epidemiologist, Paris, France, ⁶Rheumatology, Hôpital Lariboisière, Paris, France, ⁷Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁸Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁹Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁰Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ¹¹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹²Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹³Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ¹⁴Rheumatology Department, CHU de ROUEN, Rouen, France, ¹⁵Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁶Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁷Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ¹⁸Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁹Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ²⁰Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France
Background/Purpose: This study aimed to compare the efficacy and the safety of Rituximab (RTX)in elderly (aged ≥ 65years) and younger patients (aged 18-64 years) with…
Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Simon Tarp¹, Daniel Furst², John R. Kirwan³, Maarten Boers⁴, Henning Bliddal⁵, Thasia Woodworth⁶, Else Marie Bartels⁷, Bente Danneskiold-Samsoe⁵, Lars Erik Kristensen⁸, Steffen Thirstrup⁹, Mette Rasmussen⁹, Marian Kaldas¹⁰ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ³Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁴Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁵Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, ⁶Leading Edge Clinical Research LLC, Florida, FL, ⁷Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Institute for Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark, ¹⁰David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…
Abstract Number: 2170 • 2012 ACR/ARHP Annual Meeting
Methotrexate and Interstitial Lung Disease in Rheumatoid Arthritis – A Systematic Literature Review and Meta-Analysis
Richard Conway¹, Candice Low², Robert J. Coughlan³, Martin O'Donnell⁴ and John J. Carey³, ¹Rheumatology, St James's Hospital, Dublin, Ireland, ²Medicine, St. James Hospital, Dublin, Ireland, ³Rheumatology, Galway University Hospitals, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose: Methotrexate is commonly prescribed for a variety of diseases including rheumatoid arthritis. Methotrexate has frequently been implicated as a causative agent in interstitial lung…
Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting
Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Rhumatology, University Hospital of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
Abstract Number: 2172 • 2012 ACR/ARHP Annual Meeting
An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs
Susan Knowles¹, Dominick Sudano¹, Sara Taroumian², Neil M. Ampel³, John Galgiani⁴, Jeffrey R. Lisse¹ and Susan E. Hoover⁵, ¹Department of Rheumatology, University of Arizona, Tucson, AZ, ²Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ³Infectious Disease, University of Arizona, Tucson, AZ, ⁴Valley Fever Center for Excellence, Tucson, AZ, ⁵Infectious Diseases, University of Arizona, Tucson, AZ
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection in the Southwestern United States which typically causes a self-limited pulmonary illness. Patients with rheumatic disease…
Abstract Number: 2173 • 2012 ACR/ARHP Annual Meeting
Pharmacoeconomic Evaluation of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis
Navarro Sarabia F¹, Francisco J. Blanco V², Álvaro Gracia JM³, JA García Meijide⁴ and Jl Poveda⁵, ¹Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, ²Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ³Rheumatology Service, H. Universitario La Princesa, Madrid, SC, Spain, ⁴Rheumatologist Service, Hospital Ntra. Sra. La Esperanza, Santiago de Compostela, Spain, ⁵Pharmacy Service, Hospital Universitario La Fe, Valencia, Spain
Background/Purpose: ADACTA trial (Gabay C et al EULAR June 2012) showed that tocilizumab (TCZ) monotherapy was superior to adalimumab (ADA) monotherapy in reducing signs and…
Abstract Number: 2174 • 2012 ACR/ARHP Annual Meeting
Natural History of Sjögren’s Syndrome Phenotypic Features in the Sjögren’s International Collaborative Clinical Alliance Registry
Caroline Shiboski¹, Alan N. Baer², Mi Y. Lam¹, Stephen Challacombe³, Hector Lanfranchi⁴, Morten Schiødt⁵, Hisanori Umehara⁶, Frederick B. Vivino⁷, Yan Zhao⁸, Yi Dong⁸, Bruce W. Kirkham⁹, Kenneth E. Sack¹⁰, Susumu Sugai¹¹, Cristina F. Vollenweider¹², Wen Zhang⁸, John S. Greenspan¹, Troy Daniels¹³, Lindsey A. Criswell¹⁴ and Sjögren's International Collaborative Clinical Alliance¹⁵, ¹Orofacial Sciences, University of California San Francisco, San Francisco, CA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Kings College London, London, United Kingdom, ⁴University of Buenos Aires, Buenos Aires, Argentina, ⁵Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark, ⁶Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan, ⁷Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ⁸Rheumatology, PUMCH, Bejing, China, ⁹Rheum Dept/ Guys Hospital, Guys Hospital, London, United Kingdom, ¹⁰Dept of Medicine/Box0326, Univ of Calif-San Francisco, San Francisco, CA, ¹¹Kanazawa Medical University, Ishikawa, Japan, ¹²Rheumatology, German Hospital, Buenos Aires, Argentina, ¹³Orofacial Sciences, Box 0422, University of California San Francisco, San Francisco, CA, ¹⁴Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹⁵Orofacial Sciences, University of California San Francisco, University of California San Francisco, CA
Background/Purpose: Sjögren’s syndrome (SS) is known to be a relatively stable or slowly progressing disease, however, few studies have actually followed patients over time while…
Abstract Number: 2175 • 2012 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Sjogren Syndrome: A Population-Based Study
Carlotta Nannini¹, Adlene Jebakumar², Jay H. Ryu³, Cynthia S. Crowson⁴ and Eric L. Matteson², ¹Rheumatology Unit, Prato Hospital, Prato, Italy, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The reported frequency of pulmonary involvement in primary Sjögren’s Syndrome (pSS) varies widely ranging from 8 to 75% depending on the detection method employed…
Abstract Number: 2176 • 2012 ACR/ARHP Annual Meeting
Pulmonary Manifestations and Treatment of Primary Sjogren’s Syndrome-Associated Lung Involvement Patients: A Prospective Study
Hui Gao¹, Xuewu Zhang², Jing He², Min Feng², Wei Zhao¹, Yan Ding² and Zhan-guo Li², ¹Emergency department & Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Peking University People's Hospital, Peking University People's Hospital, Beijing, China
Background/Purpose: Pulmonary involvement is common in primary Sjögren’s syndrome (pSS). Clinicopathologic pulmonary manifestations associated with pSS have yet to be reviewed in a large series.…
Abstract Number: 2177 • 2012 ACR/ARHP Annual Meeting
The Forced Oscillation Technique Is a Sensitive Method for Detection of Obstructive Airway Disease in Patients with Primary Sjögren’s Syndrome
Anna M. Nilsson¹, Elke Theander², Roger Hesselstrand³, Per Wollmer⁴ and Thomas Mandl⁵, ¹Dept of Rheumatology, Skane University Hospital Malmo, Lund University, Malmo, Sweden, ²Dept of Rheumatology, Skane University Hospital Malmo, Lund University, Malmö, Sweden, ³Rheumatology, Lund University, Lund, Sweden, ⁴Dept of Clinical Physiology, Skane University Hospital Malmo, Lund University, Malmö, Sweden, ⁵Dept of Rheumatology, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden
Background/Purpose: To study signs of obstructive airway disease in patients with primary Sjögren’s syndrome (pSS) by the forced oscillation technique (FOT), a method that may…
Abstract Number: 2178 • 2012 ACR/ARHP Annual Meeting
18-Fludeoxyglucose Positron Emission Tomography Is a Valuable Marker of Activity of Interstitial Lung Disease in Primary Sjogren’s Syndrome
Camille Cohen¹, Arsene Mekinian², Michael Soussan³, Yurdagul Uzunhan⁴, Veronique Eder³, Robin Dhote⁵, Dominique Valeyre⁶ and Olivier Fain⁷, ¹Jean Verdier Hospital, Bondy, France, ²Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, ³Nuclear Medicine, Bobigny, France, ⁴Pneumology, Bobigny, France, ⁵Internal Medicine, Avicenne University Hospital, Bobigny, France, ⁶Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, ⁷Internal Medicine, Jean Verdier Hospital, Bondy, France
Background/Purpose: Purpose: To assess the value of 18-Fludeoxyglucose Positron Emission Tomography (PET) in patients with primary Sjogren's Syndrome (pSS).Methods: All patients with confirmed pSS (AECG)…
Abstract Number: 2179 • 2012 ACR/ARHP Annual Meeting
High Resolution CT Findings and Concomitant Nontuberculosis Mycobacterial Infection (NTM) in Patients with the Diagnosis of Primary Sjogren’s Syndrome Evaluated At a Respiratory Referral Center
Mehrnaz Maleki-Fischbach¹ and Gloria M. Russell², ¹Medicine, National Jewish Health, Denver, CO, ²Pontificia Universidad Católica Madre y Maestra, Santiago, Dominican Republic
Background/Purpose: Although lung disease can occur with primary Sjogren’s syndrome (pSS), far too little is known about the clinical phenotype or natural history of its lung…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].